Skip to content

Study · Randomized controlled trial · n = 16 · 2017

5 results

Repository corticotropin for Chronic Pulmonary Sarcoidosis.

Baughman RP, Sweiss N, Keijsers R, Birring SS, Shipley R, Saketkoo LA, Lower EE

Lung28 Mar 2017Cited by 64 (Europe PMC)

PMID28353116 (opens in a new tab)PMCIDPMC5437201 (opens in a new tab)DOI10.1007/s00408-017-9994-4 (opens in a new tab)PepBankPUB-28353116
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

PurposeThe dose of repository corticotropin (RCI) and need for a loading dose in sarcoidosis patients receiving chronic corticosteroids are unclear. We performed a single-blind prospective study, comparing two doses of RCI in sarcoidosis.MethodsChronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week. The dose of prednisone was modified by the clinician who was blinded to the patient's dosage of RCI.ResultsSixteen patients completed the full 24 weeks of the study. At week 24, there was a decrease in the dose of prednisone, and improvements in DLCO, King's Sarcoidosis Questionnaire health status and fatigue score. There was no significant change in FVC % predicted. For the PET scan, there was a significant fall in the standard uptake value (SUV) of the lung lesions. Only 3/8 patients remained on 80 units RCI for full 24 weeks. There was no significant difference in the response to therapy for those treated with 40- versus 80-unit RCI.ConclusionsRepository corticotropin treatment was prednisone-sparing and associated with significant improvement in DLCO, PET scan, and patient-reported outcome measures. A dose of 40-unit RCI twice a week was as effective as 80-unit RCI and was better tolerated.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chronic pulmonary sarcoidosis, response did not differ significantly between 40-unit and 80-unit repository corticotropin treatment.

    In plain wordsIn chronic pulmonary sarcoidosis, response did not differ significantly between the two repository corticotropin doses.

    Peptide
    ACTH (corticotropin)
    Outcome
    No significant changeResponse by dose
    Study

    n = 16

    Comparator
    80-unit RCI twice weekly
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    40-unit RCI twice weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in the response to therapy for those treated with 40- versus 80-unit RCI.
    1 context sentence
    Summary · context
    Chronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week.
  2. 02HumanNon-randomized trialEfficacy outcome

    In chronic pulmonary sarcoidosis, prednisone dose decreased and DLCO, questionnaire health status, and fatigue scores improved at week 24 during repository corticotropin treatment.

    In plain wordsIn chronic pulmonary sarcoidosis, prednisone dose decreased and lung diffusion, health status, and fatigue improved during repository corticotropin treatment.

    Peptide
    ACTH (corticotropin)
    Outcome
    MixedPrednisone dose, DLCO, health status and fatigue
    Study

    n = 16

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    80 units loading for 10 days, then 40 or 80 units twice weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 24, there was a decrease in the dose of prednisone, and improvements in DLCO, King's Sarcoidosis Questionnaire health status and fatigue score.
    1 context sentence
    Summary · context
    Chronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week.
  3. 03HumanNon-randomized trialEfficacy outcome

    In chronic pulmonary sarcoidosis, FVC percent predicted did not change significantly during repository corticotropin treatment.

    In plain wordsIn chronic pulmonary sarcoidosis, FVC percent predicted did not change significantly during repository corticotropin treatment.

    Peptide
    ACTH (corticotropin)
    Outcome
    No significant changeFVC percent predicted
    Study

    n = 16

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    80 units loading for 10 days, then 40 or 80 units twice weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant change in FVC % predicted.
    1 context sentence
    Summary · context
    Chronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week.
  4. 04HumanNon-randomized trialEfficacy outcome

    In chronic pulmonary sarcoidosis, lung lesion PET standard uptake value decreased significantly during repository corticotropin treatment.

    In plain wordsIn chronic pulmonary sarcoidosis, PET uptake in lung lesions decreased during repository corticotropin treatment.

    Peptide
    ACTH (corticotropin)
    Outcome
    DecreaseLung lesion PET SUV
    Study

    n = 16

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    80 units loading for 10 days, then 40 or 80 units twice weekly · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    For the PET scan, there was a significant fall in the standard uptake value (SUV) of the lung lesions.
    1 context sentence
    Summary · context
    Chronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week.
  5. 05HumanNon-randomized trialOther

    In chronic pulmonary sarcoidosis, only 3 of 8 patients remained on 80-unit repository corticotropin for the full 24 weeks.

    In plain wordsIn chronic pulmonary sarcoidosis, only 3 of 8 patients remained on 80-unit repository corticotropin for the full study.

    Peptide
    ACTH (corticotropin)
    Outcome
    Not applicablePersistence on 80-unit dose
    Study

    n = 8

    Outcome group
    Treatment adherence and retention · Respiratory
    Studied dose
    80 units twice weekly · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Patients remaining on 80-unit RCI for full 24 weeks
    3 patients
    of 8 patients on 80 units twice weekly

    Source sentences

    Summary
    Only 3/8 patients remained on 80 units RCI for full 24 weeks.
    1 context sentence
    Summary · context
    Chronic pulmonary sarcoidosis patients receiving prednisone therapy with deterioration by 5% in FVC in the previous year were studied. RCI was administered subcutaneously at a loading dose of 80 units RCI for 10 days. Patients were randomized at day 14 to receive either 40- or 80-unit RCI twice a week.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT02188017

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

University of Cincinnatin = 20Jun 2014 to est. Sept 2017

Sarcoidosis · Pulmonary Sarcoidosis

Trial pageClinicalTrials.govUpdated 8 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.